Topics covered in this new report include healthcare reform – with innovative new pricing models and a move towards outcome-based drug assessment. Additionally, there is a definite shift towards greater regulatory harmonization across Canada’s ten provinces and three territories.

Furthermore, this report unpicks the niches within the pharmaceutical value chain in which Canada is making a name for itself. These include clinical trials and contract research, biotech, genomics and medical device manufacturing. Most eye-catchingly, Canada is forging ahead in new areas such as cannabinoid-based treatments – a topic covered in depth in our special feature on medical cannabis.